Literature DB >> 30982329

Clinical 18F-FDG and amyloid brain positron emission tomography/CT in the investigation of cognitive impairment: where are we now?

Maureen Dumba1, Sairah Khan2, Neva Patel2,3, Laura Perry2,3, Paresh Malhotra4,5, Richard Perry4,5, Kuldip Nijran2,3, Tara Barwick2, Kathryn Wallitt2, Zarni Win2.   

Abstract

The number of people living with dementia is increasing, but as yet there remains no cure or disease-modifying treatment. This review aims to help readers understand the role of 18F-FDG PET/CT imaging in the investigation of cognitive impairment and how the advent of amyloid PET/CT imaging may hold the key to radically changing management of the most common form of dementia - Alzheimer's disease. The indications for 18F-FDG PET/CT and amyloid PET/CT imaging in cognitive impairment are outlined. Additionally, the mechanisms of action, technique, patient preparation and acquisition parameters for both are detailed. We conclude by providing a framework for interpreting 18F-FDG PET/CT and amyloid PET/CT imaging in the more common conditions that lead to cognitive impairment conditions with tips on avoiding pitfalls in interpretation.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30982329      PMCID： PMC6732924          DOI： 10.1259/bjr.20181027

Source DB:  PubMed          Journal:  Br J Radiol        ISSN： 0007-1285            Impact factor:   3.039


  22 in total

1.  Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010.

Authors:  Thomas G Beach; Sarah E Monsell; Leslie E Phillips; Walter Kukull
Journal:  J Neuropathol Exp Neurol       Date:  2012-04       Impact factor: 3.685

2.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Ronald C Petersen; Michael W Weiner; Paul S Aisen; Leslie M Shaw; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Vernon S Pankratz; Michael C Donohue; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2013-02       Impact factor: 44.182

3.  Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.

Authors:  Seok Rye Choi; Julie A Schneider; David A Bennett; Thomas G Beach; Barry J Bedell; Simone P Zehntner; Michael J Krautkramer; Hank F Kung; Daniel M Skovronsky; Franz Hefti; Christopher M Clark
Journal:  Alzheimer Dis Assoc Disord       Date:  2012 Jan-Mar       Impact factor: 2.703

Review 4.  PET imaging in the assessment of normal and impaired cognitive function.

Authors:  Daniel H S Silverman; Abass Alavi
Journal:  Radiol Clin North Am       Date:  2005-01       Impact factor: 2.303

5.  Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance.

Authors:  Andreas Charidimou; Karim Farid; Hsin-Hsi Tsai; Li-Kai Tsai; Rouh-Fang Yen; Jean-Claude Baron
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-10-25       Impact factor: 10.154

6.  Available from Available from A cluster of tuberculosis cases linked to smoking: An under-recognized challenge for tuberculosis elimination.

Authors:  E Rea; T Leung
Journal:  Can Commun Dis Rep       Date:  2018-03-01

7.  Clinical, FDG and amyloid PET imaging in posterior cortical atrophy.

Authors:  Tarun D Singh; Keith A Josephs; Mary M Machulda; Daniel A Drubach; Liana G Apostolova; Val J Lowe; Jennifer L Whitwell
Journal:  J Neurol       Date:  2015-04-11       Impact factor: 4.849

Review 8.  Alzheimer's disease drug development pipeline: 2017.

Authors:  Jeffrey Cummings; Garam Lee; Travis Mortsdorf; Aaron Ritter; Kate Zhong
Journal:  Alzheimers Dement (N Y)       Date:  2017-05-24

Review 9.  Tau PET imaging: present and future directions.

Authors:  Laure Saint-Aubert; Laetitia Lemoine; Konstantinos Chiotis; Antoine Leuzy; Elena Rodriguez-Vieitez; Agneta Nordberg
Journal:  Mol Neurodegener       Date:  2017-02-20       Impact factor: 14.195

Review 10.  Alzheimer's disease diagnostic criteria: practical applications.

Authors:  Jeffrey Cummings
Journal:  Alzheimers Res Ther       Date:  2012-09-05       Impact factor: 6.982
View more
  3 in total

1.  Advances in neurodegenerative and psychiatric imaging: introductory editorial.

Authors:  Amy L Kotsenas; Meike W Vernooij; John D Port
Journal:  Br J Radiol       Date:  2019-09       Impact factor: 3.039

2.  Longitudinal evaluation of a novel BChE PET tracer as an early in vivo biomarker in the brain of a mouse model for Alzheimer disease.

Authors:  Luka Rejc; Vanessa Gómez-Vallejo; Ana Joya; Oscar Moreno; Ander Egimendia; Pilar Castellnou; Xabier Ríos-Anglada; Unai Cossío; Zuriñe Baz; Rossana Passannante; Ignacio Tobalina-Larrea; Pedro Ramos-Cabrer; Albert Giralt; Magdalena Sastre; Estibaliz Capetillo-Zarate; Urban Košak; Damijan Knez; Stanislav Gobec; Mariel Marder; Abraham Martin; Jordi Llop
Journal:  Theranostics       Date:  2021-04-26       Impact factor: 11.556

3.  Evaluating cognitive profiles of patients undergoing clinical amyloid-PET imaging.

Authors:  Flavia Loreto; Stephen Gunning; Mara Golemme; Hilary Watt; Neva Patel; Zarni Win; Christopher Carswell; Richard J Perry; Paresh A Malhotra
Journal:  Brain Commun       Date:  2021-03-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.